X4 Pharmaceuticals
Tracked across 1 events · 7 articles · First seen Sep 08, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
X4 Pharmaceuticals announced a positive outcome from its Type C meeting with the United States — Food and Drug Administration regarding the global 4WARD Phase 3 clinical trial for mavorixafor in chronic neutropenia. The FDA…
Impact: X4 Pharmaceuticals is the sponsor of the 4WARD trial and the developer of mavorixafor. The FDA's agreement to reduce the sample size is a positive regulatory outcome that may reduce trial costs and accelerate development, supporting the company's stock.
Sep 08, 2026 · 7 articles
90
United States — Food and Drug Administration agreed to reduced sample size X4 PharmaceuticalsFDA Agrees to Reduced...
ERGEN INTELLIGENCE
Track X4 Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard